Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Take­da on Tues­day morn­ing made an an­nounce­ment that al­most 3,000 peo­ple with the rare dis­ease known as hy­poparathy­roidism were fear­ing.

Due to un­re­solved sup­ply is­sues and man­u­fac­tur­ing woes, Take­da said it will cut its loss­es and dis­con­tin­ue its hy­poparathy­roidism drug, known as Nat­para (parathy­roid hor­mone), halt­ing all man­u­fac­tur­ing of the drug by the end of 2024, but the en­tire in­ven­to­ry will be avail­able un­til de­plet­ed or ex­pired, a com­pa­ny spokesper­son said via email.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER